Targeting Rheumatoid Arthritis disease where it strikes — in the joints — in 70 million people worldwide
Targeting Rheumatoid Arthritis disease where it strikes — in the joints — in 70 million people worldwide DeMay Bio’s goal is to develop an adjunct therapy for Rheumatoid Arthritis that directly targets the harmful cellular changes that cause joint pain, tissue damage and disabling mobility loss. Our treatment is designed to work with a patient’s…
About DeMay Bio
Research and discovery for new disease interventions. DeMay Bio is a Connecticut biotechnology startup company founded in 2018. Our goal is to develop a new treatment for Rheumatoid Arthritis that leverages the body’s own natural defense mechanisms to block disease signs in the joints that cause pain and mobility loss for patients. Who we are: The…
Leveraging the body’s natural defense mechanisms to control Rheumatoid Arthritis joint pain and tissue damage Rheumatoid Arthritis is an auto-immune disease that causes disabling joint pain and mobility loss. Any joint can be affected. Over 70 million people worldwide have Rheumatoid Arthritis, with the disease striking women three times more often than men. Because there is no…
Dec 28, 2018: DeMay Bio selected for ABCT’s New York/Connecticut bioscience accelerator program http://www.hartfordbusiness.com/article/20181228/NEWS01/181229957/ct-backed-bioscience-accelerator-picks-2nd-cohort Feb 20, 2018: PITCH funding awarded for DeMay Bio’s technology https://pitch.yale.edu/news/uconn-health-researcher-wins-pitch-promising-project-award-potential-ra-treatment
Location: 400 Farmington Avenue, Farmington, CT 06032 If you wish to send us an email, please fill out the contact form below.